Skip to main content

Advertisement

Table 4 Value distribution of VEGF in various response groups of NSCLC patients during first-line chemotherapy

From: Efficacy of plasma vascular endothelial growth factor in monitoring first-line chemotherapy in patients with advanced non-small cell lung cancer

     P
Biomarkers (unit) Remission median (range) No Change median (range) Progression median (range) R+NC vs P R vs NC+P
VEGF BV1 (pg/mL) 364.0 (136.6-868.0) 180.5 (70.6-546.0) 286.4 (72.6-522.6) 0.589 0.083
VEGF BV2 (pg/mL) 144.0 (34.6-588.4) 237.8 (52.1-431.0) 325.2 (158.4-612.1) 0.001 0.016
VEGF BV3 (pg/mL) 119.0 (26.0-571.0) 269.7 (51.0-526.0) 402.8 (174.6-811.0) 0.001 0.001
VEGF BV1-2 (Dec%) 41.6 (2.2-86.8) -6.6 (-90.6-64.5) -18.5 (-118.2-2.7) 0.0001 0.0001
VEGF BV1-3 (Dec%) 63.0 (17.2-93.1) -3.2 (-142.2-53.0) -41.0 (-140.5- -17.8) 0.0001 0.0001
VEGF BV2-3 (Dec%) 12.7 (-62.4-87.1) -21.2 (-33.6-33.8) -15.3 (-66.3-5.3) 0.0268 0.0052
  1. BV1, BV2, and BV3, baseline VEGF levels before therapy cycle 1 to 3, respectively; BV1-2, BV1-3 and BV2-3, kinetics of baseline VEGF levels from cycles 1 to 2, 1 to 3 and 2 to 3, respectively; Dec%, decrease in percent (negative numbers meaning increase of the VEGF levels). P values by Wilcoxon test indicate differences between patients with progressive disease (P) and those having remission and stable disease (R+NC; evaluation 1) as well as between patients with remission (R) and those having progressive and stable disease (P+NC; evaluation 2).